Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CD19 (CD19 Molecule)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

HTG EdgeSeq Oncology Biomarker Panel (OBP) (2)

HTG EdgeSeq DLBCL Cell of Origin Assay

HTG EdgeSeq DLBCL Cell of Origin Assay EU

›

CD19 positive	Acute Lymphocytic Leukemia	CD19 positive	Acute Lymphocytic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1	blinatumomab Sensitive: A1 - Approval blinatumomab Sensitive : A1
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B
CD19 positive	Non-Hodgkin’s Lymphoma	CD19 positive	Non-Hodgkin’s Lymphoma	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B	CTX110 Sensitive: B - Late Trials CTX110 Sensitive : B
CD19 expression	Diffuse Large B Cell Lymphoma	CD19 expression	Diffuse Large B Cell Lymphoma	JCAR014 Sensitive: C2 – Inclusion Criteria JCAR014 Sensitive : C2	JCAR014 Sensitive: C2 – Inclusion Criteria JCAR014 Sensitive : C2
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3	CAR-T immunotherapy Sensitive: C3 – Early Trials CAR-T immunotherapy Sensitive : C3
CD19 positive + Chr t(8;21)	Acute Myelogenous Leukemia	CD19 positive + Chr t(8;21)	Acute Myelogenous Leukemia	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3	T-lymphocyte cell therapy Sensitive: C3 – Early Trials T-lymphocyte cell therapy Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	YT-19 Sensitive: C3 – Early Trials YT-19 Sensitive : C3	YT-19 Sensitive: C3 – Early Trials YT-19 Sensitive : C3
CD19 deletion	B Acute Lymphoblastic Leukemia	CD19 deletion	B Acute Lymphoblastic Leukemia	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3	blinatumomab Sensitive: C3 – Early Trials blinatumomab Sensitive : C3
CD19 positive + CD20 positive	B Acute Lymphoblastic Leukemia	CD19 positive + CD20 positive	B Acute Lymphoblastic Leukemia	CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy Sensitive : C3	CD19-targeted CAR-T immunotherapy Sensitive: C3 – Early Trials CD19-targeted CAR-T immunotherapy Sensitive : C3
CD19 positive	B Acute Lymphoblastic Leukemia	CD19 positive	B Acute Lymphoblastic Leukemia	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3	tisagenlecleucel-T Sensitive: C3 – Early Trials tisagenlecleucel-T Sensitive : C3
CD19 mutation	Diffuse Large B Cell Lymphoma	CD19 mutation	Diffuse Large B Cell Lymphoma	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3	axicabtagene ciloleucel Resistant: C3 – Early Trials axicabtagene ciloleucel Resistant : C3